Search results for "double-blind method"

showing 10 items of 631 documents

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Resul…

2017

Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment. A pilot phase IIIB, multicentre, prospective, placebo controlled, randomized, double blinded study of 12 weeks follow-up was performed (NCT01197846). Patients were randomized to quetiapine XR …

MaleBipolar Disorder*Bipolar disorderPilot Projectslaw.invention0302 clinical medicineRandomized controlled triallawAntimanic AgentsAmbulatory CarePharmacology (medical)*QuetiapineMood stabilizerMiddle AgedSubthreshold symptomsPsychiatry and Mental healthTreatment OutcomeNeurologyDrug Therapy CombinationFemalemedicine.symptomPsychologySomnolencemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classBipolar disorderPlacebo03 medical and health sciencesQuetiapine FumarateYoung AdultDouble-Blind MethodInternal medicinemedicineHumans*Subthreshold symptomsBipolar disorderPsychiatryAdverse effectBiological PsychiatryAgedPharmacologyPsychiatric Status Rating ScalesQuetiapineBody Weightmedicine.disease030227 psychiatryMoodDelayed-Action PreparationsQuetiapineNeurology (clinical)030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease R…

2017

Introduction: There is a growing interest in nutraceuticals improving cardiovascular risk factor levels and related organ damage. Methods: This double-blind, placebo-controlled randomized clinical trial aims to compare the effect of a combined nutraceutical containing red yeast rice (10 mg), phytosterols (800 mg), and l-tyrosol (5 mg) on lipid profile, blood pressure, endothelial function, and arterial stiffness in a group of 60 patients with polygenic hypercholesterolemia resistant to Mediterranean diet. Results: After 8 weeks of treatment, when compared to the placebo group, the active treated patients experienced a more favorable percentage change in total cholesterol (−16.3% vs 9.9…

MaleBlood Pressure030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compoundDietary supplement0302 clinical medicineRisk FactorsPhytosterolPharmacology (medical)030212 general & internal medicineEndothelial dysfunctionOriginal ResearchFramingham Risk Scoremedicine.diagnostic_testAnticholesteremic AgentsFatty liverPhytosterolsGeneral MedicineMiddle AgedDietary supplementsCholesterolBiochemistryCardiovascular DiseasesFemaleNutraceuticalsNutraceuticalAdultmedicine.medical_specialtyl-TyrosolHypercholesterolemiaPlacebo03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansRisk factorBiological ProductsCholesterolbusiness.industryHemodynamicsmedicine.diseaseCardiovascular disease riskBlood pressurechemistryRed yeast riceArterial stiffnessLipid profilebusinessBiomarkers
researchProduct

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

2012

Aims High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport protein (CETP) inhibitor torcetrapib raised blood pressure (BP), impaired endothelial function, and increased CV mortality and morbidity. Dalcetrapib is a novel molecule acting on CETP with a different chemical structure to torcetrapib. As HDL stimulates nitric oxide (NO), suppresses inflammation, and exerts protective CV effects, we investigated the effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipids in patients with, o…

MaleBrachial ArteryBlood PressureCoronary Diseasechemistry.chemical_compoundAnacetrapibTorcetrapibMedicineLipoproteinbiologyAnticholesteremic AgentsEstersMiddle AgedVasodilationTreatment OutcomeCardiologyFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineBlood Flow Velocitymedicine.medical_specialtyAmbulatory blood pressureDalcetrapibHypercholesterolemia610 Medicine & healthPlacebo142-005 142-0052705 Cardiology and Cardiovascular MedicineCholesterol (HDL-C)Double-Blind MethodInternal medicineCholesterylester transfer proteinDalcetrapibHumansSulfhydryl CompoundsTriglyceridesAgedbusiness.industryCholesterol HDLTorcetrapibCholesterol LDLAmidesFasttrack ClinicalCholesterol Ester Transfer ProteinsEndocrinologyBlood pressurechemistrybiology.proteinHigh-density570 Life sciences; biologyEndothelium VascularbusinessBiomarkersEvacetrapibEuropean heart journal
researchProduct

Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis

2017

Nasal nitric oxide (nNO) is a noninvasive tool that may be helpful in evaluating the inflammatory status in the upper airways [1]. Previous studies report that nNO is elevated in children with Allergic Rhinitis (AR) [2], especially in perennial sensitized subjects [3], and that it may be affected by topical administration of intranasal steroids (INSs) [4]. This article is protected by copyright. All rights reserved.

MaleBudesonideRhinitis Allergic PerennialImmunologyAdministration Intranasal; Budesonide; Child; Double-Blind Method; Eosinophils; Female; Glucocorticoids; Humans; Male; Nasal Obstruction; Nitric Oxide; Rhinitis Allergic Perennial; Sleep; Pediatrics Perinatology and Child Health; Immunology and Allergy; ImmunologyNitric OxidePediatricsNitric oxidelaw.invention03 medical and health scienceschemistry.chemical_compoundAllergic0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansImmunology and AllergyMedicineChild030223 otorhinolaryngologyBudesonideGlucocorticoidsChildrenAdministration IntranasalRhinitisbusiness.industryPerinatology and Child HealthNitric oxide metabolismPerennialNasal obstructionNasal nitric oxideEosinophilsIntranasal030228 respiratory systemchemistryAnesthesiaAdministrationPediatrics Perinatology and Child HealthFemaleNasal administrationSleepbusinessmedicine.drug
researchProduct

Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controll…

2006

To evaluate the efficacy and tolerability of a novel hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) formulation of budesonide (Pulmicort) versus the conventional chlorofluorocarbon (CFC) pMDI formulation in paediatric patients with asthma.This was a Phase III, multicentre, 12-week, double-blind, randomised, parallel-group study involving children (6-12 years of age) with mild to moderate asthma. Patients received either budesonide HFA pMDI or budesonide CFC pMDI 200 mug twice daily, with or without a spacer (NebuChamber/Nebunette). Primary efficacy endpoint: mean percentage change in forced expiratory volume in 1 second (FEV(1)) from baseline to week 12. Secondary efficacy …

MaleBudesonideVital capacityHydrocarbons FluorinatedPeak Expiratory Flow Ratelaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawmedicineHumansMetered Dose InhalersBudesonideChildAsthmaChlorofluorocarbonbusiness.industryInhalerGeneral Medicinemedicine.diseaseMetered-dose inhalerAsthmaBronchodilator AgentsTreatment OutcomeAerosol PropellantschemistryTolerabilityAnesthesiaFemaleChlorofluorocarbonsbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study

2002

Aims and Background Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain, even though no specific studies have demonstrated a benefit. A randomized placebo-controlled, double-blind crossover study was designed to evidence the effects of amitriptyline in patients with neuropathic cancer pain. Methods Sixteen advanced cancer patients with neuropathic pain on systemic morphine therapy, no longer receiving oncologic treatment, presenting moderate pain (about 4 or more, but less than 7, on a numerical scale of 0-10) in the last week, and given a stable morphine dose in the last 2 days were admitted to the study. During the first week of study, patient…

MaleCancer ResearchAmitriptylineAnalgesicPlaceboNeuropathic painDrug Administration Schedule03 medical and health sciences0302 clinical medicineDouble-Blind Method030502 gerontologyRandomized controlled studyNeoplasmsmedicineHumansAmitriptylineCancer painAgedPain MeasurementAged 80 and overCross-Over StudiesMorphinebusiness.industryGeneral MedicineAnalgesics Non-NarcoticMiddle AgedCrossover studyAnalgesics OpioidTreatment OutcomeOncologyOpioid030220 oncology & carcinogenesisAnesthesiaNeuropathic painQuality of LifeMorphineNeuralgiaDrug Therapy CombinationFemaleAnalgesic0305 other medical scienceCancer painbusinessmedicine.drug
researchProduct

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acut…

2012

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/d…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateVentricular Function Leftlaw.inventionchemistry.chemical_compoundVentricular Dysfunction LeftRandomized controlled trialRamiprillawRisk FactorsOdds RatioMyocardial infarctionProspective Studieseducation.field_of_studyEjection fractionGeneral MedicineMiddle AgedZofenoprilEuropeHospitalizationTreatment OutcomeCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugRamiprilmedicine.medical_specialtySystolePopulationClinical InvestigationsRisk AssessmentDouble-Blind MethodInternal medicinemedicineHumanseducationAgedHeart FailureChi-Square DistributionAspirinbusiness.industryStroke Volumeacetylsalicylic acidmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryLogistic ModelschemistryAngiotensin-converting enzyme inhibitorHeart failureMyocardial infarction complicationsZofenopril ramipril myocardial infarctionbusinessPlatelet Aggregation Inhibitors
researchProduct

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron : The Myocardial- Trial

2020

Background Intravenous ferric carboxymaltose ( FCM ) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Methods and Results Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were eval…

MaleCardiac magnetic resonance*ferric carboxymaltoseMagnetic Resonance Imaging (MRI)Myocardial ironAnèmia*heart failure030204 cardiovascular system & hematologyFerric Compounds0302 clinical medicine030212 general & internal medicineOriginal Researchcardiac magnetic resonance ferric carboxymaltose heart failure iron deficiency myocardial ironAnemia Iron-DeficiencyAnemiaIron deficiencyMiddle AgedMyocardial ironMagnetic Resonance Imaging*myocardial ironMagnetic resonanceCardiologyAdministration IntravenousFemaleCardiology and Cardiovascular Medicine*cardiac magnetic resonancemedicine.medical_specialtyNoninvasive imagingCardiomyopathyIronIntravenous ironHeart failureFERRIC CARBOXYMALTOSE03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltoseAgedPharmacologybusiness.industryMyocardiumIron deficiencyRessonància magnèticaMiocardimedicine.diseaseFerric carboxymaltoseTreatmentHeart failureHematinicsbusinessCardiac magnetic resonance*iron deficiencyFerro
researchProduct

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.

2015

Background Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. Aim To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC). Methods This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome meas…

MaleColorectal cancerResistancelcsh:MedicineAdministration OralArtesunatePilot ProjectsPharmacologyGastroenterologyPlacebosNeutropaeniachemistry.chemical_compoundCancerlcsh:R5-920medicine.diagnostic_testGeneral MedicineImmunohistochemistryArtemisininsDihydroartemisininTreatment OutcomeTolerabilityOriginal ArticleFemalelcsh:Medicine (General)Colorectal NeoplasmsKi67medicine.medical_specialtyRandomizationPlaceboGeneral Biochemistry Genetics and Molecular BiologyDouble-Blind MethodMedian follow-upInternal medicineBiopsymedicineBiomarkers TumorHumansAgedDemographyStaining and Labelingbusiness.industrylcsh:Rmedicine.diseaseColorectal cancerSurvival AnalysisCarcinoembryonic AntigenMalariaClinical trialKi-67 AntigenchemistryArtesunateCommentarybusinessEBioMedicine
researchProduct